These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 8532940)

  • 1. [The current status of the prevention and treatment of sudden death].
    Pedrote A; Errazquin F
    Rev Esp Cardiol; 1995 Nov; 48(11):710-21. PubMed ID: 8532940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sudden death and hypertrophic cardiomyopathy: a review.
    Ly HQ; Greiss I; Talakic M; Guerra PG; Macle L; Thibault B; Dubuc M; Roy D
    Can J Cardiol; 2005 Apr; 21(5):441-8. PubMed ID: 15861263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of sudden cardiac death.
    Goldberger JJ
    Heart Dis; 2000; 2(4):305-13. PubMed ID: 11728274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk stratification and prevention of sudden death in patients with heart failure].
    Villacastín J; Bover R; Castellano NP; Moreno J; Morales R; García-Espinosa A
    Rev Esp Cardiol; 2004 Aug; 57(8):768-82. PubMed ID: 15282066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary prevention of sudden cardiac death using implantable cardioverter defibrillators.
    Ding L; Hua W; Niu H; Chen K; Zhang S
    Europace; 2008 Sep; 10(9):1034-41. PubMed ID: 18559335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure.
    Winslow RD; Pinney S; Fuster V
    Nat Clin Pract Cardiovasc Med; 2006 Feb; 3(2):86-93. PubMed ID: 16446777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sudden cardiac death: the role of risk stratification.
    Kusmirek SL; Gold MR
    Am Heart J; 2007 Apr; 153(4 Suppl):25-33. PubMed ID: 17394900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial--a prospective pilot study.
    de Bie MK; Lekkerkerker JC; van Dam B; Gaasbeek A; van Buren M; Putter H; van Erven L; Bax JJ; Schalij MJ; Rabelink TJ; Jukema JW
    Curr Med Res Opin; 2008 Aug; 24(8):2151-7. PubMed ID: 18561878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
    Prystowsky EN
    Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials update: sudden cardiac death prevention by implantable device therapy.
    Finch NJ; Leman RB
    Crit Care Nurs Clin North Am; 2005 Mar; 17(1):33-8, x. PubMed ID: 15749399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death.
    Das M
    Expert Rev Cardiovasc Ther; 2009 Feb; 7(2):181-95. PubMed ID: 19210214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ventricular tachycardia and sudden cardiac death.
    Reddy PC; Tandon N; Stafford PR
    J La State Med Soc; 1999 May; 151(5):281-7. PubMed ID: 10363484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sudden death: from epidemiology to therapeutic management-prevention].
    Aliot E
    Arch Mal Coeur Vaiss; 2000 Jun; Spec No():27-9. PubMed ID: 10949712
    [No Abstract]   [Full Text] [Related]  

  • 18. Prevention of sudden cardiac death: the role of the implantable cardioverter-defibrillator.
    Sinha SK; Mehta D; Gomes JA
    Mt Sinai J Med; 2005 Jan; 72(1):1-9. PubMed ID: 15682255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk stratification for sudden cardiac death: should we juist consider ejection fraction?].
    Paolucci M; Cattafi G; Magenta G; Vecchi MR; Schirru M; Lunati M
    G Ital Cardiol (Rome); 2008 Oct; 9(10 Suppl 1):27S-32S. PubMed ID: 19195303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death.
    Klein MH; Gold MR
    Cardiol Clin; 2008 Aug; 26(3):419-31, vi-vii. PubMed ID: 18538188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.